NLM Digital Collections

Search

Search Constraints

Start Over You searched for: Copyright Public domain Remove constraint Copyright: Public domain Publication Year 2000 to 2023 Remove constraint Publication Year: <span class="from" data-blrl-begin="2000">2000</span> to <span class="to" data-blrl-end="2023">2023</span>

Search Results

1. Data inadequacies undermine CMS's oversight of the inconsistency resolution process for the federal marketplace

2. CMS validated hospital inpatient quality reporting program data, but should use additional tools to identify gaming

4. CDC generally met its inspection goals for the federal select agent program: however, opportunities exist to strengthen oversight

6. Round 2 competitive bidding for CPAP/RAD: disrupted access unlikely for devices, inconclusive for supplies

8. OHRP generally conducted its compliance activities independently, but changes would strengthen its independence

9. HHS's Office of Refugee Resettlement improved coordination and outreach to promote the safety and well-being of unaccompanied alien children

10. Medicare program shared savings accountable care organizations have shown potential for reducing spending and improving quality

13. As funding for BPA research increased, NIEHS followed its peer review process while also exercising its discretion

15. Medicare Part B drug payments: impact of price substitutions based on 2014 average sales prices

17. Drug supply chain security: wholesalers exchange most tracing information

22. Enhancements needed in the tracking and collection of Medicare overpayments identified by ZPICS and PSCS

23. A few states fell short in timely investigation of the most serious nursing home complaints: 2011-2015

25. Medicare Part B drug payments: impact of price substitutions based on 2015 average sales prices

26. Medicare payments for clinical diagnostic laboratory tests in 2016: year 3 of baseline data

27. Excluding noncovered versions when setting payment for two Part B drugs would have resulted in lower drug costs for Medicare and its beneficiaries

28. Medicaid Fraud Control Units: investigation and prosecution of fraud and beneficiary abuse in Medicaid personal care services

29. Followup review: CMS's management of the quality payment program

30. Potential misclassifications reported by drug manufacturers may have led to $1 billion in lost Medicaid rebates

31. Entities' experiences and perceptions of reporting the theft, loss, or release of select agents or toxins to CDC

32. Drug supply chain security: dispensers received most tracing information

34. Round two competitive bidding for oxygen: continued access for vast majority of beneficiaries

35. Round two competitive bidding for enteral nutrition: continued access for vast majority of beneficiaries

36. HRSA helped health centers with elevated risks and can continue to take additional steps

38. Part D plans generally include drugs commonly used by dual eligibles: 2018

40. Entities generally met Federal Select Agent Program internal inspection requirements, but CDC could do more to improve effectiveness

41. Opioid use in Medicare Part D remains concerning

42. CMS did not detect some inappropriate claims for durable medical equipment in nursing facilities

43. Opioids in Ohio Medicaid: review of extreme use and prescribing

46. Medicare Part B drug payments: impact of price substitutions based on 2016 average sales prices

47. Questionable billing for compounded topical drugs in Medicare Part D

48. FDA should further integrate its review of cybersecurity into the premarket review process for medical devices

49. Treatment planning and medication monitoring were lacking for children in foster care receiving psychotropic medication

50. Medicare payments for clinical diagnostic laboratory tests in 2017: year 4 of baseline data

54. Medicare Advantage appeal outcomes and audit findings raise concerns about service and payment denials

55. States follow a common framework in responding to breaches of Medicaid data

56. Hospitals reported improved preparedness for emerging infectious diseases after the Ebola outbreak

58. Possible higher spending paths for veterans' benefits

62. Review of access and quality of care in SCHIP using standardized national performance measures

63. Pharmacogenomics: a primer for policymakers

64. Fairfax County's commitment: a housing and health continuum for seniors : site visit report

67. The aging services network: accomplishments and challenges in serving a growing elderly population

71. High hopes: public health approaches to reducing the need for health care

73. Schedule H: new community benefit reporting requirements for hospitals

81. The role of ombudsmen in assuring quality for residents of long-term care facilities: straining to make ends meet

82. No free lunch?: current challenges facing National School Lunch and School Breakfast Programs

83. The medical education of physicians

85. Children's behavioral health services in Baltimore: walking the continuum : site visit report

89. The budget and economic outlook: 2018 to 2028

91. Federal subsidies for health insurance coverage for people under age 65: 2018 to 2028

92. Federal mandatory spending for means-tested programs, 2008 to 2028

93. How CBO adjusts for survey underreporting of transfer income in its distributional analyses

95. Figura matricis

96. Health document submission requirements for tobacco products: (revised)

97. Registration and product listing for owners and operators of domestic tobacco product establishments: (revised)

98. BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment

99. Regulatory classification of pharmaceutical co-crystals

100. Duchenne muscular dystrophy and related dystrophinopathies: developing drugs for treatment